Categories
Recommended Sites
- Affordable Web Hosting
- Bed Bug Registry
- Bing Search
- Conscious Evolution
- Cryomedical Blog
- Free Health Insurance Quote
- Free Loan Quote
- Genistein Net
- Google Search
- HGH
- HGH Injections
- HGH Prescription
- HGH Side Effects
- HGH Therapy
- Hormone Therapy
- Injectable Testosterone
- Medical School Review
- New York City Real Estate
- Palm Beach Real Estate
- SEO Web Design
- Start Your Own Internet Services Company
- Testosterone Injections
- Testosterone Replacement Therapy
- WholeSale Domain Names
- Yahoo Search
Category Archives: Stem Cell Human Trials
Editor’s move sparks backlash
Bioethicist Glenn McGee’s new job raised questions of conflict of interest at the journal he founded. J. Continue reading
Posted in Stem Cell Human Trials
Tagged advice, england, houston, kansas, medicine, president, press-release, publisher-, south-korea, texas
Comments Off
Bioethics Backlash
Bioethicists debate how to remain impartial as a bioethics journal editor joins a company that peddles unproven stem cell therapies. Continue reading
Posted in Stem Cell Human Trials
Tagged advancement, ajob-on-march, bioethicists, clinical-trials-, edyta-zielinska, passes-the-test, school-district, science, such-as-insoo, university, weekend-at-the, while-remaining, wireless, wireless-drug
Comments Off
VistaGen Therapeutics Engages MissionIR as Its Investor Relations Advisor
ATLANTA, GA–(Marketwire -02/21/12)- VistaGen Therapeutics, Inc. (OTC.BB: VSTA.OB – News) (OTCQB: VSTA.OB – News), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has retained MissionIR, a national investor relations consulting firm, to develop and implement a strategic investor relations campaign. Continue reading
Posted in Stem Cell Human Trials
Tagged a-full-suite, a-serious-and, change-the-way, clients, director, healthcare, human-clinical, investment, marketing, peripheral, phase, shareholder, technology-for, therapeutics
Comments Off
Penn State: Inspiring Collaboration – Video -3
02-02-2012 15:43 Penn State scientists find an inspiring collaboration. Dr. Prabhu, who specializes in the health benefits of fish oil, and Dr. Continue reading
Posted in Stem Cell Human Trials
Tagged a-weekly-faculty, connected-their, fish-oil, health, possible-cure, scientists-find, seemingly, seemingly-separate, state--, stem, stem-cells, the-health
Comments Off
MissionIR News – VistaGen Therapeutics Selects Top 10 Candidates for Stem Cell Technology-Based Drug Rescue Programs
Company plans launch of two drug rescue programs by end of next quarter Atlanta, GA (PRWEB) February 16, 2012 MissionIR would like to highlight VistaGen Therapeutics, Inc. Continue reading
Posted in Stem Cell Human Trials
Tagged a-for-heart, business, chief-executive, clients, communications, companies-, facebook, human-clinical, investment, mission, reputation, rescue-programs, securities, shareholders, vista
Comments Off
ACT gets another trial site for stem cell therapy
Wednesday, February 15, 2012 By Rodney Brown Advanced Cell Technology Inc. has added an institute in Philadelphia as another site where it is conducting trials of its stem cell-based treatment of an eye condition that can cause blindness Continue reading
Posted in Stem Cell Human Trials
Tagged a-site-for, board, embryonic-stem, institute, jules-stein, news-followed, philadelphia, released-data, robert-langer, rodney-brown, stargardt, trial-at-ucla
Comments Off
Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for …
MARLBOROUGH, Mass.–(BUSINESS WIRE)– Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Wills Eye Institute in Philadelphia has received institutional review board (IRB) approval as a site for the company’s Phase I/II clinical trial for Stargardt’s Macular Dystrophy (SMD), a form of juvenile macular degeneration, using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. Earlier this year, the Company also announced that the IRB at Wills Eye Institute had approved the participation of the institution as a site for ACT’s clinical trial for dry age-related macular degeneration (dry AMD). Continue reading
Posted in Stem Cell Human Trials
Tagged a-site-for, circumstances, country, emergency, institute, news, philadelphia, safety, statements, technology, time, university, words, world-report
Comments Off
Stemedica Granted U.S. Patent for Cellular Scaffold
Stemedica has been issued U.S. Patent #8,105,380 by the United States Patent and Trademark Office. This broad-based patent covers the combination of scaffolds with stem cells derived from ectodermal and mesenchymal tissue Continue reading
Posted in Stem Cell Human Trials
Tagged a-product-will, chairman, patent, president, stemedica, stemedica-cell, technologies, trademark
Comments Off
ACT Announces Third Patient with Stargardt’s Disease Treated in U.S. Clinical Trial with RPE Cells Derived from …
MARLBOROUGH, Mass.–(BUSINESS WIRE)– Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the dosing of third patient in its Phase 1/2 trial for Stargardt’s macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient was treated on Monday (Feb. Continue reading
Posted in Stem Cell Human Trials
Tagged advanced-cell, california, circumstances, data-, development, europe, first, medicine, news, ophthalmology, stargardt, statements, technology, time
Comments Off